Intraperitoneal Chemotherapy in the Management of Ovarian Cancer: Focus on Carboplatin

Overview

Journal Ther Clin Risk Manag

Publisher Dove Medical Press

Date 2009 May 14

PMID 19436618

Citations 5

Authors

Maurie Markman

Affiliations

Soon will be listed here.

Abstract

Both pre-clinical studies and phase 1-2 clinical trials have provided strong support for the potential role of regional drug delivery in the management of epithelial ovarian cancer, a disease process whose major manifestations remain largely localized to the peritoneal cavity in the majority of individuals with this malignancy. The results of 3 phase 3 randomized trials have revealed the favorable impact of primary cisplatin-based intraperitoneal chemotherapy in women who initiate drug treatment with small-volume residual ovarian cancer following an attempt at optimal surgical cytoreduction. Concerns have been raised regarding the toxicity of regional treatment, particularly the side-effect profile associated with cisplatin. One rational approach to improving the tolerability of intraperitoneal chemotherapy is to substitute carboplatin for cisplatin. This review discusses the rationale for and data supporting regional treatment of epithelial ovarian cancer, and highlights the potential role for intraperitoneal carboplatin in this clinical setting.

Citing Articles

Photoimmunotherapy and irradiance modulation reduce chemotherapy cycles and toxicity in a murine model for ovarian carcinomatosis: perspective and results.

Rizvi I, Dinh T, Yu W, Chang Y, Sherwood M, Hasan T Isr J Chem. 2013; 52(8-9):776-787.

PMID: 23626376 PMC: 3634612. DOI: 10.1002/ijch.201200016.

Vectors for inhaled gene therapy in lung cancer. Application for nano oncology and safety of bio nanotechnology.

Zarogouldis P, Karamanos N, Porpodis K, Domvri K, Huang H, Hohenforst-Schimdt W Int J Mol Sci. 2012; 13(9):10828-10862.

PMID: 23109824 PMC: 3472716. DOI: 10.3390/ijms130910828.

Differential routes of carboplatin administration influence lymphocyte apoptosis in retroperitoneal lymph nodes.

Huang Y, Zeng Z, Li S, Liu J Tumour Biol. 2012; 33(6):2053-9.

PMID: 22843332 DOI: 10.1007/s13277-012-0464-6.

Synergistic enhancement of carboplatin efficacy with photodynamic therapy in a three-dimensional model for micrometastatic ovarian cancer.

Rizvi I, Celli J, Evans C, Abu-Yousif A, Muzikansky A, Pogue B Cancer Res. 2010; 70(22):9319-28.

PMID: 21062986 PMC: 3057933. DOI: 10.1158/0008-5472.CAN-10-1783.

Targeted quantitative analysis of superoxide dismutase 1 in cisplatin-sensitive and cisplatin-resistant human ovarian cancer cells.

Kim J, Nie B, Sahm H, Brown D, Tegeler T, You J J Chromatogr B Analyt Technol Biomed Life Sci. 2010; 878(7-8):700-4.

PMID: 20117967 PMC: 2827867. DOI: 10.1016/j.jchromb.2010.01.013.

References

Barakat R, Almadrones L, Venkatraman E, Aghajanian C, Brown C, Shapiro F . A phase II trial of intraperitoneal cisplatin and etoposide as consolidation therapy in patients with Stage II-IV epithelial ovarian cancer following negative surgical assessment. Gynecol Oncol. 1998; 69(1):17-22. DOI: 10.1006/gyno.1998.4973. View

Hess L, Benham-Hutchins M, Herzog T, Hsu C, Malone D, Skrepnek G . A meta-analysis of the efficacy of intraperitoneal cisplatin for the front-line treatment of ovarian cancer. Int J Gynecol Cancer. 2007; 17(3):561-70. DOI: 10.1111/j.1525-1438.2006.00846.x. View

Elit L, Oliver T, Covens A, Kwon J, Fung M, Hirte H . Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: a systematic review with metaanalyses. Cancer. 2007; 109(4):692-702. DOI: 10.1002/cncr.22466. View

Los G, Verdegaal E, Mutsaers P, McVie J . Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy. Cancer Chemother Pharmacol. 1991; 28(3):159-65. DOI: 10.1007/BF00685503. View

Los G, Mutsaers P, van der Vijgh W, Baldew G, de Graaf P, McVie J . Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. Cancer Res. 1989; 49(12):3380-4. View

Pretorius R, Hacker N, Berek J, FORD L, Hoeschele J, Butler T . Pharmacokinetics of Ip cisplatin in refractory ovarian carcinoma. Cancer Treat Rep. 1983; 67(12):1085-92. View

Shapiro F, Schneider J, Markman M, Reichman B, Venkatraman E, Barakat R . High-intensity intravenous cyclophosphamide and cisplatin, interim surgical debulking, and intraperitoneal cisplatin in advanced ovarian carcinoma: a pilot trial with ten-year follow-up. Gynecol Oncol. 1997; 67(1):39-45. DOI: 10.1006/gyno.1997.4821. View

Fujiwara K, Sakuragi N, Suzuki S, Yoshida N, Maehata K, Nishiya M . First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up. Gynecol Oncol. 2003; 90(3):637-43. DOI: 10.1016/s0090-8258(03)00377-9. View

Kraft A, Tompkins R, Jesseph J . Peritoneal electrolyte absorption: analysis of portal, systemic venous, and lymphatic transport. Surgery. 1968; 64(1):148-53. View

10.

Markman M, Reichman B, Hakes T, Lewis Jr J, Jones W, Rubin S . Impact on survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small-volume residual ovarian cancer. J Clin Oncol. 1992; 10(9):1479-84. DOI: 10.1200/JCO.1992.10.9.1479. View

11.

Howell S, Pfeifle C, Wung W, Olshen R, Lucas W, YON J . Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med. 1982; 97(6):845-51. DOI: 10.7326/0003-4819-97-6-845. View

12.

Lukas G, BRINDLE S, Greengard P . The route of absorption of intraperitoneally administered compounds. J Pharmacol Exp Ther. 1971; 178(3):562-4. View

13.

Casper E, Kelsen D, Alcock N, Lewis Jr J . Ip cisplatin in patients with malignant ascites: pharmacokinetic evaluation and comparison with the iv route. Cancer Treat Rep. 1983; 67(3):235-8. View

14.

Markman M . Intraperitoneal antineoplastic drug delivery: rationale and results. Lancet Oncol. 2003; 4(5):277-83. DOI: 10.1016/s1470-2045(03)01074-x. View

15.

Elferink F, van der Vijgh W, Klein I, Ten Bokkel Huinink W, Dubbelman R, McVie J . Pharmacokinetics of carboplatin after intraperitoneal administration. Cancer Chemother Pharmacol. 1988; 21(1):57-60. DOI: 10.1007/BF00262740. View

16.

du Bois A, Luck H, Meier W, Adams H, Mobus V, Costa S . A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst. 2003; 95(17):1320-9. DOI: 10.1093/jnci/djg036. View

17.

Markman M . Critical thinking: an essential role in both the conduct and interpretation of gynecologic cancer clinical research. Gynecol Oncol. 2007; 108(3):462-5. DOI: 10.1016/j.ygyno.2007.10.006. View

18.

Litterst C, Collins J, Lowe M, Arnold S, Powell D, Guarino A . Local and systemic toxicity resulting from large-volume ip administration of doxorubicin in the rat. Cancer Treat Rep. 1982; 66(1):157-61. View

19.

Markman M, Belinson J . A rationale for neoadjuvant systemic treatment followed by surgical assessment and intraperitoneal chemotherapy in patients presenting with non-surgically resectable ovarian or primary peritoneal cancers. J Cancer Res Clin Oncol. 2004; 131(1):26-30. DOI: 10.1007/s00432-004-0624-1. View

20.

SUHRLAND L, WEISBERGER A . INTRACAVITARY 5-FLUOROURACIL IN MALIGNANT EFFUSIONS. Arch Intern Med. 1965; 116:431-3. DOI: 10.1001/archinte.1965.03870030111019. View